Pelthos Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. (ticker: PTHS) is a U.S.-based biopharmaceutical company listed on NYSE American in the United States, with a focused strategy centered on commercializing differentiated dermatology-oriented therapeutic products. The company’s current identity reflects a strategic transformation completed in 2025, including a name change from Channel Therapeutics Corporation, which underscores a shift toward a more commercial biopharma model rather than a legacy development-stage structure. Pelthos is headquartered in Durham, North Carolina, and its disclosed facility there serves both as corporate headquarters and as the company’s primary manufacturing site for berdazimer sodium API used in ZELSUVMI. Its public filings emphasize a mission to address unmet treatment burdens through innovative, safe, and effective products. The company’s near-term investment story is built around ZELSUVMI™ (berdazimer) topical gel, 10.3%, which Pelthos identifies as its lead product. The asset is positioned as a differentiated prescription topical therapy for a contagious viral skin condition, with the notable convenience of being usable at home by patients, parents, or caregivers rather than only in a physician’s office or similar medical setting. That at-home administration profile is an important commercial differentiator and potentially supports broader access and ease of adoption. From an equity analyst perspective, Pelthos therefore represents a concentrated commercial-stage biotechnology case: upside is tied to one flagship product and its market penetration, while execution risk remains elevated because of the company’s limited diversification. Historically, Pelthos’ current form emerged from a restructuring and transaction-driven repositioning in 2025, including the reverse stock split and the conversion into a NYSE American-listed issuer under the PTHS symbol. The company’s recent corporate history also includes an acquisition-related transition and the launch of Pelthos as a standalone biopharmaceutical platform. That background matters because it signals that management is still in the early phases of building the operating model, the commercial infrastructure, and the revenue base. In other words, the investment thesis is less about a mature product portfolio and more about the successful ramp of a niche specialty asset. Competitively, Pelthos operates in a specialized segment of dermatology/infectious skin disease where clinical differentiation, usability, and physician acceptance matter more than scale alone. It is much smaller than large U.S. pharmaceutical peers, but the company aims to carve out a defensible position through product specificity and a lean cost structure. Recent public disclosures in 2026 show continued SEC activity and corporate updates, reflecting an issuer that remains in build-out mode and under close investor scrutiny. For investors in France, Belgium, and Switzerland, Pelthos should be viewed as a U.S. small-cap health and pharma name with a high-variance profile: meaningful product-driven optionality, but also meaningful dependence on execution, manufacturing consistency, and market uptake of ZELSUVMI.